Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
In the Intensive Care (IC)-unit moxifloxacin treatment is often started with intravenous
administrations. As moxifloxacin is known to have a high oral bioavailability in healthy
volunteers, patients are switched to oral or enteral therapy as soon as possible. However, no
data on plasma levels for moxifloxacin during such a switch-therapy in IC-patients are
available. Therefore, this study aims to evaluate the moxifloxacin-plasma levels and their
inter-individual variability during IV to enteral switch therapy in IC-patients.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Ghent
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination